Flamel Technologies SA (NASDAQ:FLML) shares shot up 1.9% on Wednesday . The company traded as high as $13.72 and last traded at $13.66, with a volume of 60,900 shares changing hands. The stock had previously closed at $13.40.

A number of brokerages have recently weighed in on FLML. Zacks Investment Research upgraded Flamel Technologies SA from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Leerink Swann restated a “buy” rating and set a $16.00 price objective on shares of Flamel Technologies SA in a research report on Tuesday, May 10th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $18.63.

The firm has a market cap of $583.15 million and a P/E ratio of 34.24. The stock’s 50-day moving average is $12.44 and its 200 day moving average is $10.80.

Flamel Technologies SA (NASDAQ:FLML) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.08. During the same period in the previous year, the company posted $0.34 earnings per share. The company had revenue of $38.90 million for the quarter, compared to the consensus estimate of $32.80 million. The company’s quarterly revenue was down 20.0% compared to the same quarter last year. On average, equities research analysts predict that Flamel Technologies SA will post ($1.11) EPS for the current year.

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.